UPSTREAM BIO, INC. Payments of Stock Issuance Costs
UPSTREAM BIO, INC. (UPB) reported Payments of Stock Issuance Costs of $34.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-03-26
- UPSTREAM BIO, INC. payments of stock issuance costs for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- UPSTREAM BIO, INC. payments of stock issuance costs for the quarter ending 2025-06-30 was $0.00.
- UPSTREAM BIO, INC. payments of stock issuance costs for the quarter ending 2025-03-31 was $34.00K.
- UPSTREAM BIO, INC. payments of stock issuance costs for the quarter ending 2024-12-31 was $2.11M.
- UPSTREAM BIO, INC. payments of stock issuance costs for fiscal 2024 was $3.90M.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $34.00K 10-Q · filed 2025-11-05 | $2.14M derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $34.00K 10-Q · filed 2025-08-06 | $2.14M derived: sum of 3 quarters · filed 2026-03-26 | $3.80M derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-03-31 | $34.00K 10-Q · filed 2025-05-06 | $2.14M derived: sum of 2 quarters · filed 2026-03-26 | $3.80M derived: sum of 3 quarters · filed 2026-03-26 | |
| 2024-12-31 | $2.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $3.77M derived: sum of 2 quarters · filed 2026-03-26 | $3.90M 10-K · filed 2026-03-26 | |
| 2024-09-30 | $1.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.79M 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $133.00K 10-Q · filed 2025-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |